MOH
Molina Healthcare IncHealth Careinsider_universeEverything we've seen
- ?Nov 13, 7:30 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
MOH (Molina Healthcare) is a managed care organization with no company-specific negative news in the 30-day window to explain the ~10.8% drawdown from its 30-day high. The SEC filings (10-Q and 8-K from late October 2026) contain no reported metrics flagging deterioration, and there are no headlines indicating guidance cuts or operational issues. The macro context (elevated mortgage rates) is largely irrelevant to a Medicaid/managed care insurer, so the drop appears to be driven by broader sector rotation or market noise rather than fundamental deterioration.
- !Nov 13, 7:30 PMsignalseverity 0.11
Agent 4 — Dip Buyer (Frozen) — dip_skipped
MOH (Molina Healthcare) is a managed care organization with no company-specific negative news in the 30-day window to explain the ~10.8% drawdown from its 30-day high. The SEC filings (10-Q and 8-K from late October 2026) contain no reported metrics flagging deterioration, and there are no headlines indicating guidance cuts or operational issues. The macro context (elevated mortgage rates) is largely irrelevant to a Medicaid/managed care insurer, so the drop appears to be driven by broader sector rotation or market noise rather than fundamental deterioration.
- ?Nov 13, 3:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- !Nov 13, 3:20 PMsignalseverity 0.11
Agent 5 — Dip Buyer (Evolving) — dip_skipped
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- ?Nov 13, 3:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- !Nov 13, 3:20 PMsignalseverity 0.11
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- ?Nov 13, 2:21 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- !Nov 13, 2:21 PMsignalseverity 0.11
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- ?Nov 13, 2:21 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- !Nov 13, 2:21 PMsignalseverity 0.11
Agent 5 — Dip Buyer (Evolving) — dip_skipped
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- ?Nov 13, 1:23 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- !Nov 13, 1:23 PMsignalseverity 0.12
Agent 5 — Dip Buyer (Evolving) — dip_skipped
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- ?Nov 13, 1:23 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- !Nov 13, 1:23 PMsignalseverity 0.12
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- ?Nov 13, 12:20 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
MOH is down 1.70% intraday, a modest but real move suggesting some selling pressure. There are no catalysts or headlines to anchor the move directionally, making it ambiguous whether this is informed flow or noise. The macro context (T10Y2Y at 2.0σ below trend, favoring defensives in a bear-flattening environment) is mildly supportive of defensive/managed care names like MOH, which could act as a headwind to continued downside — but MOH is not a pure defensive and managed care has its own idiosyncratic pressures. With 205 minutes remaining, there is ample time for the move to continue if momentum is real, but also ample time for a reversal if this is a morning flush with no follow-through. The absence of news cuts both ways. The move magnitude (~1.7%) is below the 2-5% 'high conviction' threshold. On balance, this is a borderline read — slight continuation bias given the asymmetric system parameters (bounded downside stop, fixed target), but no strong structural reason to press the short side aggressively. Probability set at the threshold floor.
- !Nov 13, 12:20 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
MOH is down 1.70% intraday, a modest but real move suggesting some selling pressure. There are no catalysts or headlines to anchor the move directionally, making it ambiguous whether this is informed flow or noise. The macro context (T10Y2Y at 2.0σ below trend, favoring defensives in a bear-flattening environment) is mildly supportive of defensive/managed care names like MOH, which could act as a headwind to continued downside — but MOH is not a pure defensive and managed care has its own idiosyncratic pressures. With 205 minutes remaining, there is ample time for the move to continue if momentum is real, but also ample time for a reversal if this is a morning flush with no follow-through. The absence of news cuts both ways. The move magnitude (~1.7%) is below the 2-5% 'high conviction' threshold. On balance, this is a borderline read — slight continuation bias given the asymmetric system parameters (bounded downside stop, fixed target), but no strong structural reason to press the short side aggressively. Probability set at the threshold floor.
- ?Nov 13, 11:36 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- !Nov 13, 11:36 AMsignalseverity 0.12
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- ?Nov 12, 7:30 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
MOH (Molina Healthcare) is a managed care organization with no company-specific negative news in the 30-day window to explain the ~10.8% drawdown from its 30-day high. The SEC filings (10-Q and 8-K from late October 2026) contain no reported metrics flagging deterioration, and there are no headlines indicating guidance cuts or operational issues. The macro context (elevated mortgage rates) is largely irrelevant to a Medicaid/managed care insurer, so the drop appears to be driven by broader sector rotation or market noise rather than fundamental deterioration.
- !Nov 12, 7:30 PMsignalseverity 0.10
Agent 4 — Dip Buyer (Frozen) — dip_skipped
MOH (Molina Healthcare) is a managed care organization with no company-specific negative news in the 30-day window to explain the ~10.8% drawdown from its 30-day high. The SEC filings (10-Q and 8-K from late October 2026) contain no reported metrics flagging deterioration, and there are no headlines indicating guidance cuts or operational issues. The macro context (elevated mortgage rates) is largely irrelevant to a Medicaid/managed care insurer, so the drop appears to be driven by broader sector rotation or market noise rather than fundamental deterioration.
- ?Nov 12, 2:36 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- !Nov 12, 2:36 PMsignalseverity 0.10
Agent 5 — Dip Buyer (Evolving) — dip_skipped
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- ?Nov 12, 11:06 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
MOH is down 1.75% intraday with no headline catalyst visible, suggesting this is flow/technical driven selling rather than a news event that might quickly reverse. The move is meaningful but not extreme. Macro context shows 10Y inflation breakevens printing 1.7σ below trend, which is a mild tailwind for managed care/health insurers (lower inflation expectations reduce medical cost inflation fears), but this is a subtle effect and unlikely to reverse intraday selling pressure mid-session. With 280 minutes remaining (well over 4 hours until forced close), there is ample time for the move to extend further. No reversal signals or news catalyst to fade the selling are evident. The absence of news is not disqualifying — large institutional flow often lacks a public headline. Continuation probability is modest rather than strong because the macro backdrop is not overtly bearish for MOH and the move size (~1.75%) is moderate rather than a capitulation-style flush. Overall, slight lean toward continuation of the downside into the close.
- !Nov 12, 11:06 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
MOH is down 1.75% intraday with no headline catalyst visible, suggesting this is flow/technical driven selling rather than a news event that might quickly reverse. The move is meaningful but not extreme. Macro context shows 10Y inflation breakevens printing 1.7σ below trend, which is a mild tailwind for managed care/health insurers (lower inflation expectations reduce medical cost inflation fears), but this is a subtle effect and unlikely to reverse intraday selling pressure mid-session. With 280 minutes remaining (well over 4 hours until forced close), there is ample time for the move to extend further. No reversal signals or news catalyst to fade the selling are evident. The absence of news is not disqualifying — large institutional flow often lacks a public headline. Continuation probability is modest rather than strong because the macro backdrop is not overtly bearish for MOH and the move size (~1.75%) is moderate rather than a capitulation-style flush. Overall, slight lean toward continuation of the downside into the close.
- ?Nov 12, 10:20 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- !Nov 12, 10:20 AMsignalseverity 0.13
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- ?Nov 12, 10:20 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- !Nov 12, 10:20 AMsignalseverity 0.13
Agent 5 — Dip Buyer (Evolving) — dip_skipped
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- ?Nov 12, 9:20 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- ?Nov 12, 9:20 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- !Nov 12, 9:20 AMsignalseverity 0.11
Agent 5 — Dip Buyer (Evolving) — dip_skipped
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- !Nov 12, 9:20 AMsignalseverity 0.11
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- ?Nov 11, 7:31 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
MOH (Molina Healthcare) is a managed care organization with no company-specific negative news in the 30-day window to explain the ~10.8% drawdown from its 30-day high. The SEC filings (10-Q and 8-K from late October 2026) contain no reported metrics flagging deterioration, and there are no headlines indicating guidance cuts or operational issues. The macro context (elevated mortgage rates) is largely irrelevant to a Medicaid/managed care insurer, so the drop appears to be driven by broader sector rotation or market noise rather than fundamental deterioration.
- !Nov 11, 7:31 PMsignalseverity 0.11
Agent 4 — Dip Buyer (Frozen) — dip_skipped
MOH (Molina Healthcare) is a managed care organization with no company-specific negative news in the 30-day window to explain the ~10.8% drawdown from its 30-day high. The SEC filings (10-Q and 8-K from late October 2026) contain no reported metrics flagging deterioration, and there are no headlines indicating guidance cuts or operational issues. The macro context (elevated mortgage rates) is largely irrelevant to a Medicaid/managed care insurer, so the drop appears to be driven by broader sector rotation or market noise rather than fundamental deterioration.
- ?Nov 11, 2:21 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- !Nov 11, 2:21 PMsignalseverity 0.11
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- ?Nov 11, 2:21 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- !Nov 11, 2:20 PMsignalseverity 0.11
Agent 5 — Dip Buyer (Evolving) — dip_skipped
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- ?Nov 11, 1:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- !Nov 11, 1:20 PMsignalseverity 0.11
Agent 5 — Dip Buyer (Evolving) — dip_skipped
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- ?Nov 11, 1:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- !Nov 11, 1:20 PMsignalseverity 0.11
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- ?Nov 11, 12:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- !Nov 11, 12:20 PMsignalseverity 0.11
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- ?Nov 11, 12:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- !Nov 11, 12:20 PMsignalseverity 0.11
Agent 5 — Dip Buyer (Evolving) — dip_skipped
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- ?Nov 11, 10:21 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- ?Nov 11, 10:21 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- !Nov 11, 10:21 AMsignalseverity 0.12
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- !Nov 11, 10:21 AMsignalseverity 0.12
Agent 5 — Dip Buyer (Evolving) — dip_skipped
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- ?Nov 11, 9:21 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- !Nov 11, 9:21 AMsignalseverity 0.12
Agent 5 — Dip Buyer (Evolving) — dip_skipped
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- ?Nov 11, 9:21 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- !Nov 11, 9:21 AMsignalseverity 0.12
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- ?Nov 10, 7:31 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
MOH (Molina Healthcare) is a managed care organization with no company-specific negative news in the 30-day window to explain the ~10.8% drawdown from its 30-day high. The SEC filings (10-Q and 8-K from late October 2026) contain no reported metrics flagging deterioration, and there are no headlines indicating guidance cuts or operational issues. The macro context (elevated mortgage rates) is largely irrelevant to a Medicaid/managed care insurer, so the drop appears to be driven by broader sector rotation or market noise rather than fundamental deterioration.
- !Nov 10, 7:31 PMsignalseverity 0.12
Agent 4 — Dip Buyer (Frozen) — dip_skipped
MOH (Molina Healthcare) is a managed care organization with no company-specific negative news in the 30-day window to explain the ~10.8% drawdown from its 30-day high. The SEC filings (10-Q and 8-K from late October 2026) contain no reported metrics flagging deterioration, and there are no headlines indicating guidance cuts or operational issues. The macro context (elevated mortgage rates) is largely irrelevant to a Medicaid/managed care insurer, so the drop appears to be driven by broader sector rotation or market noise rather than fundamental deterioration.
- ?Nov 10, 2:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- !Nov 10, 2:20 PMsignalseverity 0.13
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- ?Nov 10, 2:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- !Nov 10, 2:20 PMsignalseverity 0.13
Agent 5 — Dip Buyer (Evolving) — dip_skipped
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- ?Nov 10, 1:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- ?Nov 10, 1:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- ?Nov 10, 12:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- ?Nov 10, 12:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- ?Nov 10, 11:20 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- ?Nov 10, 11:20 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- ?Nov 9, 12:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- ?Nov 9, 12:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- ?Nov 9, 11:20 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- ?Nov 9, 11:20 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- ?Nov 9, 10:21 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- ?Nov 9, 10:21 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- ?Nov 9, 9:20 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- ?Nov 9, 9:20 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- ?Nov 9, 6:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- ?Nov 9, 6:01 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- ?Nov 6, 7:32 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
MOH (Molina Healthcare) is a managed care organization with no company-specific negative news in the 30-day window to explain the ~10.8% drawdown from its 30-day high. The SEC filings (10-Q and 8-K from late October 2026) contain no reported metrics flagging deterioration, and there are no headlines indicating guidance cuts or operational issues. The macro context (elevated mortgage rates) is largely irrelevant to a Medicaid/managed care insurer, so the drop appears to be driven by broader sector rotation or market noise rather than fundamental deterioration.
- ?Nov 6, 2:20 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
MOH is down 4.31% intraday with no attributed headline, suggesting institutional selling or sector rotation rather than a news-driven spike that might quickly reverse. The absence of a catalyst cuts both ways — no short-squeeze trigger, but also no obvious reason for a snap reversal. The macro context (elevated mortgage rates at 7.18%, 1.9σ above trend) is not directly relevant to managed care/health insurance names like MOH, so it neither supports nor undermines continuation. With 85 minutes remaining there is reasonable time for momentum to persist into the close, though at this stage of the session some mean-reversion is possible as buyers probe support. The move magnitude (>4%) is significant and suggests real conviction from sellers. No reversal pattern or volume concern identified from available data. Overall, slight lean toward continuation given the size of the move and adequate time remaining, but confidence is modest — probability sits just above the neutral threshold.
- ?Nov 6, 1:21 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MOH is down 11.2% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider selling, and no imminent earnings risk (next report is 89 days away). The Health Care sector is showing strong relative strength (+13.35pts vs SPY over 30 days), suggesting this dip is idiosyncratic rather than sector-wide, which warrants some caution but also implies the broader tailwind remains supportive. The 10-Q filed Oct 22 shows no reported metrics flagging deterioration, and the macro context (elevated VIX at 98th pct, high 10Y yield) creates a headwind but is not company-specific.
- ?Nov 6, 1:21 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
MOH has recovered from the prior stop-out level ($181.43) to $208.12, suggesting some underlying resilience, and healthcare (XLV) is a top-3 performing sector with strong 30d relative strength (+13.35pts vs SPY), indicating the dip is not sector-driven. However, the evidence stack is weak: no insider buying, no unusual call flow (put/call ratio of 1.43 is modestly bearish), and the 10-Q/8-K filings contain no disclosed metrics to confirm fundamental soundness. The re-entry context adds caution — the recovery from the stop-out appears to be mean reversion rather than a catalyst-driven re-rating, with no news headlines or insider activity to ground the thesis.
- ❖Oct 1, 7:33 AMnewsvia finnhub
1 Small-Cap Stock Worth Investigating and 2 We Question
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
- ▣Sep 30, 8:00 PMjournalstop
Agent 5 — Dip Buyer (Evolving) closed long 5 @ $181.43 (-$84.50)
intraday stop sweep
- ❖Sep 30, 7:01 AMnewsvia finnhub
Diamond Hill Capital Sees Long-Term Value in Molina Healthcare (MOH) After Recent Pressure
Diamond Hill Capital, a First Eagle Investment Management company, issued its Q2 2026 investor letter for its “Select Strategy”. A copy of the letter can be downloaded here. The Strategy delivered 5.08% (net of fees) in the quarter, while the Russell 3000 Index returned 15.44%, supported by AI-driven investment, strong corporate earnings, and easing geopolitical concerns. […]
- ❖Sep 29, 5:30 AMnewsvia finnhub
The S&P 500's Thanksgiving Leftovers In September 2026
One of 2025's Thanksgiving Leftover stocks has been removed from the S&P 500. We find that 8 of the 10 Leftover stocks have dropped below the values recorded for each on November 28, 2025.
- ❖Sep 28, 8:40 AMnewsvia finnhub
Should Value Investors Buy Molina Healthcare (MOH) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- ❖Sep 23, 1:58 PMnewsvia finnhub
Can Oscar Health Sustain Its Profit Rebound as Medical Costs Rise?
Oscar Health's profit rebound faces a test as rising medical spending and a larger member base threaten second-half profitability.
- ❖Sep 23, 11:16 AMnewsvia finnhub
UNH vs. MOH: Which Managed Care Stock Looks More Attractive?
Molina Healthcare's Medicaid recovery, Medicare duals growth and contract wins support a focused turnaround story, positioning it ahead of UnitedHealth.
- ❖Sep 22, 7:30 AMnewsvia finnhub
Molina to End Its Medicare Advantage Drug Plans on December 31. The Decision Was Announced in February. The Letter Telling Members Arrives in October
Molina told investors in February that a Medicare drug plan serving tens of thousands of members would cease to exist. The members found out in October. Here is what that eight-month silence means for anyone still holding that plan card.
- ❖Sep 22, 7:01 AMnewsvia finnhub
How Centene's Strong Cash Flow Is Reshaping Its Balance Sheet
Centene's robust cash flow is helping cut debt, with a lower debt-to-capital ratio and added liquidity reshaping its balance sheet.
- ❖Sep 22, 5:10 AMnewsvia finnhub
'Vance-Led Task Force Set to Remove 760,000 Allegedly Fraudulent Obamacare Enrollments' - WSJ Exclusive
https://www.wsj.com/politics/policy/vance-led-task-force-set-to-remove-760-000-allegedly-fraudulent-obamacare-enrollments-0fbb72d7
- ❖Sep 22, 2:14 AMnewsvia finnhub
Molina Healthcare (MOH) Pulls Back Following Recent Weakness, Is The Stock Cheap?
Molina Healthcare (MOH) drew fresh attention after recent trading left the stock around $197.80, with returns down 1.5% on the day and roughly 7.6% over the past week. That pullback comes after a year where Molina Healthcare’s share price return is up 10.8% year to date, yet the 1 year total shareholder return is a more modest 8.8% and the 3 year total shareholder return shows a 42.1% decline, which suggests that recent momentum is rebuilding from a weaker long term base. See how Molina...
- ▢Sep 21, 8:00 PMjournal
Agent 7 — Day Trader opened short 15 @ $192.00
- ▣Sep 21, 8:00 PMjournaltime_stop
Agent 7 — Day Trader closed short 15 @ $191.18 (+$12.22)
EOD forced close — day trader never carries overnight
- ❖Sep 21, 9:46 AMnewsvia finnhub
Molina Healthcare (MOH) Jumped 70.7% in Q2: Why the Stock Rally Was Enough to Sell
Kopernik Global Investors recently released its “Global All-Cap Fund” second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund faced a difficult investment environment in the second quarter of 2026, as momentum-driven markets and soaring semiconductor stocks sharply favored growth-oriented equities over the fund’s value-focused approach. Class I shares declined 6.60% […]
- ❖Sep 15, 1:15 PMnewsvia finnhub
Here’s How Much You Would Have Made Owning Molina Healthcare Stock In The Last 20 Years
Molina Healthcare (NYSE:MOH) has outperformed the market over the past 20 years by 2.46% on an annualized basis producing an average annual return of 11.61%. Currently, Molina Healthcare has a market capitalization of
- ▣Sep 10, 8:00 PMjournaltime_stop
Agent 20 — SIR Price/Volume closed long 11 @ $204.23 (+$13.09)
Time stop: held 94 ≥ 90 days
- ❖Sep 10, 3:46 PMnewsvia finnhub
Michael Burry Dumps Nvidia and Palantir Put Options in Fresh Risk Warning
Burry Pulls the Trigger on Nvidia and Palantir Put Options as Market Risks Rise
- ❖Sep 10, 6:02 AMnewsvia finnhub
Wealthfront, Orchestra Biomed, AeroVironment And Other Big Stocks Moving Higher On Thursday
U.S. stocks fell, but Wealthfront surged 6.6% after beating Q2 earnings and revenue estimates; Orchestra Biomed, Clover Health and AeroVironment also rose.
- ❖Sep 9, 11:40 AMnewsvia finnhub
Michael Burry Sells NVDA, PLTR December 2026 Puts Amid Portfolio-Wide Cuts – Says He’s ‘Pulling Back’ On Risk
Burry remains short Nvidia and Palantir and still holds 2027 puts on Palantir and QQQ.
- ❖Sep 8, 3:03 PMnewsvia finnhub
Health Insurance Providers Stocks Q2 Recap: Benchmarking Molina Healthcare (NYSE:MOH)
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the health insurance providers industry, including Molina Healthcare (NYSE:MOH) and its peers.
- ❖Sep 3, 4:31 AMnewsvia finnhub
1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 25.1% over the past six months, topping the S&P 500 by 13.1 percentage points.
- ❖Sep 2, 2:58 PMnewsvia finnhub
Oscar Health Membership Surges but Profitability Remains Key
Oscar Health's membership jumps 46% to 2.96 million, but seasonal enrollment and medical utilization keep profitability in focus.
- ❖Sep 2, 10:00 AMnewsvia finnhub
Molina Healthcare Announces Third Quarter 2026 Earnings Release and Conference Call Dates
LONG BEACH, Calif., September 02, 2026--Molina Healthcare, Inc. (NYSE: MOH) today announced it will issue its earnings release for the third quarter ending September 30, 2026, after the market closes on Wednesday, October 21, 2026, and will host a conference call and webcast to discuss the earnings release on Thursday, October 22, 2026, at 8:00 a.m. Eastern Time. To access this interactive teleconference, dial (877) 883-0383 and enter the confirmation number, 6534841. A telephonic replay of the
- ❖Sep 1, 2:48 PMnewsvia finnhub
Oscar Health Skyrockets 109% YTD: Time to Bet on the Stock Now?
Oscar Health has surged 109% YTD as membership, revenue and expansion plans strengthen, though its price-to-book multiple tops the industry average.
- ❖Aug 31, 1:30 AMnewsvia finnhub
Michael Burry Bought Beaten-Down Stocks And Shorted AI Favorites — Here’s How His August Bets Fared
The AI rally put Burry’s bearish stance under pressure as Palantir, CoreWeave, Oracle, Micron, Tesla, Nebius and Nvidia all climbed during August.
- ❖Aug 27, 4:06 AMnewsvia finnhub
The S&P 500's Thanksgiving Leftovers In August 2026
August 2026 was a good month overall for the Thanksgiving Leftover Stocks of 2025.
- ❖Aug 25, 3:45 PMnewsvia finnhub
Here’s How Much You Would Have Made Owning Molina Healthcare Stock In The Last 20 Years
Molina Healthcare (NYSE:MOH) has outperformed the market over the past 20 years by 1.81% on an annualized basis producing an average annual return of 11.02%. Currently, Molina Healthcare has a market capitalization of
- ❖Jul 29, 11:52 AMnewsvia finnhub
UnitedHealth's Cost-Control Story is Gaining Momentum: Time to Buy?
UNH's improving cost control, lower medical costs and higher 2026 outlook are boosting confidence as its profitability recovery gains traction.
- ❖Jul 29, 4:25 AMnewsvia finnhub
Molina Healthcare: Management Has Made The Difficult Decision For Long-Term Benefit
Molina Healthcare (MOH) is upgraded to Buy with ~20% upside, driven by strategic ACA exit and Medicaid strength.
- ❖Jul 28, 8:40 PMnewsvia finnhub
Oakmark Global All Cap Strategy Q2 2026 Portfolio Performance
The Oakmark Global All Cap Strategy returned 8.05% in Q2 2026, trailing its benchmark due to headwinds in software and media. Read the full analysis for more.
- ❖Jul 28, 1:59 PMnewsvia finnhub
Oscar Health Flashes Buy Signal As Medicaid Weighs On Centene
S&P 500 health insurer Centene blew away Q2 earnings forecasts amid lower-than-expected Affordable Care Act Marketplace benefit costs. Oscar Health, a pure play on the ACA, flashed an early entry buy signal amid Centene's good news and a big price target hike.
- ❖Jul 28, 11:22 AMnewsvia finnhub
S&P 500 Stock Centene Dives On Medicaid Outlook
S&P 500 health insurer Centene blew away Q2 earnings forecasts amid lower-than-expected Affordable Care Act Marketplace benefit costs. CNC stock initially moved higher, but shares reversed sharply lower as the company discussed its outlook, including slightly higher Medicaid attrition and a more costly covered population in the second half of 2026. Centene posted Q2 earnings of $2.51 a share, crushing forecasts of $1.09 by $1.42 a share.
- ❖Jul 28, 10:18 AMnewsvia finnhub
Centene Finds Profit Growth Even as Medicaid Membership Softens
Centene beat Q2 earnings and revenue estimates, raised its 2026 outlook, improved medical cost trends, and reported lower Medicaid membership.
- ❖Jul 28, 4:59 AMnewsvia finnhub
Wells Fargo Maintains Equal-Weight on Molina Healthcare, Lowers Price Target to $220
Wells Fargo analyst Stephen Baxter maintains Molina Healthcare (NYSE:MOH) with a Equal-Weight and lowers the price target from $235 to $220.
- ❖Jul 28, 4:05 AMnewsvia finnhub
The S&P 500's Thanksgiving Leftovers In July 2026
July 2026 saw positive changes overall for the Thanksgiving Leftover portfolio made up of the ten worst-performing stocks in the S&P 500 as of Thanksgiving 2025. Read more here...
- ▢Jul 26, 8:00 PMjournal
Agent 5 — Dip Buyer (Evolving) opened long 5 @ $198.33
- ❖Jul 25, 6:06 AMnewsvia finnhub
Molina Healthcare (MOH) Plans Big 2027 ACA Pullback After Profit Pressure
Molina Healthcare (NYSE:MOH) plans to significantly scale back its Affordable Care Act business from 2027. The company intends to limit ACA operations to six states and reduce premiums by a meaningful margin. The move follows ongoing pressure on ACA profitability, including falling membership and higher medical costs. Molina Healthcare, trading at $197.55, is restructuring its portfolio as it responds to challenges in the ACA segment. The stock is up 10.7% year to date and 19.7% over the...
- ❖Jul 24, 12:39 PMnewsvia finnhub
Can Humana Beat Q2 Earnings Estimates on Growing Premiums?
HUM enters Q2 earnings with strong premium and membership growth expectations, but rising medical costs and expenses could test its bottom line.
- ❖Jul 24, 10:06 AMnewsvia finnhub
Truist Securities Maintains Hold on Molina Healthcare, Lowers Price Target to $225
Truist Securities analyst David Macdonald maintains Molina Healthcare (NYSE:MOH) with a Hold and lowers the price target from $250 to $225.
- ❖Jul 24, 9:40 AMnewsvia finnhub
Are Investors Undervaluing Molina Healthcare (MOH) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- ❖Jul 24, 7:06 AMnewsvia finnhub
RBC Capital Maintains Sector Perform on Molina Healthcare, Lowers Price Target to $218
RBC Capital analyst Ben Hendrix maintains Molina Healthcare (NYSE:MOH) with a Sector Perform and lowers the price target from $248 to $218.
- ❖Jul 24, 6:19 AMnewsvia finnhub
Barclays Maintains Underweight on Molina Healthcare, Lowers Price Target to $180
Barclays analyst Andrew Mok maintains Molina Healthcare (NYSE:MOH) with a Underweight and lowers the price target from $184 to $180.
- ❖Jul 23, 5:07 PMnewsvia finnhub
Molina Healthcare Q2 Earnings Call Highlights
Molina Healthcare (NYSE:MOH) reported second-quarter 2026 adjusted earnings per share of $1.51 on $10.2 billion of premium revenue, with management pointing to steady Medicaid performance and stronger-than-expected Medicare duals results while acknowledging continued pressure in its Marketplace busi
- ❖Jul 23, 4:30 PMnewsvia finnhub
Molina Healthcare, Inc. (MOH) Q2 2026 Earnings Call Transcript
Molina Healthcare, Inc. (MOH) Q2 2026 Earnings Call July 23, 2026 8:00 AM EDTCompany ParticipantsJeffrey Geyer - Head of Investor RelationsJoseph Zubretsky...
- ❖Jul 23, 3:01 PMnewsvia finnhub
Molina Healthcare Inc (MOH) Q2 2026 Earnings Call Highlights: Strong Medicaid Performance Amid ...
Molina Healthcare Inc (MOH) reports robust earnings and revenue growth, but faces hurdles in its Marketplace segment and regulatory pressures.
- ❖Jul 23, 2:07 PMnewsvia finnhub
MOH Q2 Earnings Beat on Lower Operating Expenses, 2026 EPS View Raised
Molina beats Q2 earnings estimates as lower operating expenses offset weaker premium revenues, declining membership and softer investment income, while the company raises its 2026 earnings guidance.
- ❖Jul 23, 9:28 AMnewsvia finnhub
Molina Healthcare Stung By Membership Decline, Stocks Sinks 12%
Molina Healthcare (MOH) reported Q2 earnings of $1.51 per share, beating estimates. Shares fell on lower premium revenue and membership.
- ❖Jul 23, 9:16 AMnewsvia finnhub
Brent Tops $100, Alphabet, Tesla Sink Nasdaq 100: Stock Market Today
Stocks slide Thursday as Brent crude breaks $100 and the 10-year yield hits an 18-month high, while Alphabet and Tesla earnings revive AI-spending doubts.
- ❖Jul 23, 8:30 AMnewsvia finnhub
Molina Healthcare, Inc. Q2 2026 Earnings Call Summary
Moby summary of Molina Healthcare, Inc.'s Q2 2026 earnings call
- ❖Jul 23, 7:24 AMnewsvia finnhub
Molina plans additional ACA cuts in 2027
Molina’s second quarter was complicated, with stability in Medicaid and outperformance in Medicare Advantage overshadowed by problems in the ACA exchanges. The trend was “unfortunate,” according to the insurer’s CEO.
- ❖Jul 23, 6:34 AMnewsvia finnhub
Molina Healthcare shares fall after weak revenue outlook overshadows earnings beat (NYSE:MOH)
Molina Healthcare (NYSE:MOH) shares dropped more than 9% in premarket trading on Thursday after the health insurer issued a full-year revenue outlook that disappointed investors, despite reporting second-quarter earnings ahead of market expectations. While profitability exceeded forecasts, concerns over slowing revenue growth and ongoing Medicaid headwinds weighed heavily on market sentiment.
- ❖Jul 23, 4:03 AMnewsvia finnhub
Rollins Posts Downbeat Q2 Earnings, Joins Texas Instruments, Alphabet And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
Stock futures down on Thursday, Rollins Inc (ROL) reports disappointing Q2 results, other stocks also decline in pre-market trading.
- ▢Jul 22, 8:00 PMjournal
Agent 7 — Day Trader opened short 14 @ $207.59
- ▣Jul 22, 8:00 PMjournaltarget
Agent 7 — Day Trader closed short 14 @ $201.22 (+$89.18)
Short target: close $201.22 ≤ target $201.36
- ❖Jul 22, 6:35 PMnewsvia finnhub
Molina Healthcare Earnings Beat Estimates. The Medicaid Insurer Is Confronting Investor Doubts.
Molina healthcare has seen its stock edge down in recent days amid concerns about Medicaid cost pressures.
- ❖Jul 22, 6:30 PMnewsvia finnhub
Here's What Key Metrics Tell Us About Molina (MOH) Q2 Earnings
The headline numbers for Molina (MOH) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- ❖Jul 22, 5:55 PMnewsvia finnhub
Molina (MOH) Q2 Earnings Top Estimates
Molina (MOH) delivered earnings and revenue surprises of +10.22% and -0.08%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- ▢Jun 8, 8:00 PMjournal
Agent 20 — SIR Price/Volume opened long 11 @ $203.04